Comments and feedback from listeners are always welcome!
If you enjoy listening to the podcast, do share on social media and/or consider leaving a review or rating on iTunes. With 300,000+ podcasts competing for ears, we rely on listeners to help us reach a wider audience. Below is a sample of some of the reviews and feedback we’ve received. If we’ve missed a review you’ve done, do send us a note. We’re always keen to hear what you like (or don’t like) and what we could do better. Thanks for your support!
Apple iTunes US Reviews
Novel Targets – Science worth your time by YFacio
Fascinating, short, succinct. The information is presented clearly and in a way that anyone can understand. Having had cancer, I can say that learning more about it and what we are doing to fight it is hopeful. Thanks to Novel Targets for bringing new information to the masses.
Great to Hear from Leaders in Science by kirk802
These podcasts are excellent. Reading medical journal articles can be (is) numbing after a while. The recent podcasts are excellent in bringing true experts who can and do cut through to the key points and topics (helped along by excellent questions from Peter).
— James L Gulley MDPhD (@gulleyj1) May 21, 2017
— Paul D. Rennert (@PDRennert) May 5, 2017
Right, that was another big takeaway from this great podcast: cancer immunotherapy could be the very definition of “*personalized* medicine”
— David Maizenberg (@biologypartners) May 5, 2017
February 2017 Review by @ohmsonite
— ohmsonite (@ohmsonite) February 1, 2017
Excerpt from @ohmsonite review. My favs: episode 5 : Titans of Adoptive Cell Therapy (Dr Carl June & Dr Rosenberg duke it out, in the most friendly and professional way about TCR and CAR T therapies), episode 11 (Dan Chen & Ira Mellman talk about the world famous cancer immunity cycle). Sometimes I go back and listen numerous times during my commute and frankly, I learn something new each time. If you like them, make sure you subscribe to them in iTunes and give them the reviews they so very deserve.
— Marseille Immunopole (@Immunopole) November 2, 2016
“We are at the beginning of a new era…of developing effective therapies” – George Coukos, Ludwig Lausanne director https://t.co/OHMZW6FCe4
— Ludwig Cancer (@Ludwig_Cancer) November 3, 2016
— Miguel Perales M.D. (@DrMiguelPerales) November 30, 2016
— Brad Loncar (@bradloncar) August 17, 2016
— RegenerativeMedicine (@CryoportConsult) August 17, 2016
— Oleg Kolupaev (@okolupaev) August 17, 2016
In a June 23, 2016 post on Adventures In Living Terminally Optimistic Blog, patient advocate, and stage 4 colorectal cancer patient, Tom Marsilje, PhD (@CurrentincurSci) picked up on the message of “hope” in the podcast. In several blog posts, Tom shared his excitement about the potential breakthrough in microsatellite stable (MSS) CRC where responses were seen with a combination of two drugs, neither of which worked on their own previously. Tom’s review of the podcast highlights the importance of patient education. With the increasing complexity around new treatment options and clinical trials, if you want to live as long as possible, you need be an educated patient!
— Michael Sola (@michaelsola) June 23, 2016
— UbiVac (@UbiVac) May 21, 2016
— Myeloma Teacher (@MyelomaTeacher) May 20, 2016
— (((DieterHovekamp))) (@dhovekamp42) April 30, 2016
Sticking w/ Dr Chen’s cycling analogy-I’m more excited for S2 Novel Targets than the 2016 Tour d’France – great E11! https://t.co/WICQyQikMO
— Andy Kinley (@AndyKinley) April 29, 2016
Novel Targets made Luke Timmerman’s Top 10 list on Forbes
Thanks for the shout-out Luke!
— Luke Timmerman (@ldtimmerman) April 24, 2016
Feedback on Season 1
Following Episode 10: New Horizons in Hematology, a CLL patient sent an email to say:
“I am an avid consumer of research and interviews in CLL. This is truly one of the best interviews I’ve have ever read/heard. Very comprehensive.”
An important takeaway from the feedback we’ve received from cancer patients is that many have a high-level of knowledge about their disease. They want to be informed and educated about the latest research and what new treatment options may be on the horizon. They never know when they might relapse or progress and be in need a clinical trial that offers renewed hope.
Can’t speak highly enough about @TargetsPodcast . Always educational AND great production
— PropThink (@PropThinker) November 27, 2015
— Myeloma Teacher (@MyelomaTeacher) November 25, 2015
— Oleg Kolupaev (@okolupaev) November 25, 2015
Thank you @TargetsPodcast for your excellent work illuminating immunotherapy for the masses.
— Coleman Kennedy (@biotechkcw) September 22, 2015
— Krishna Komanduri (@drkomanduri) August 21, 2015
— NovelTargets Podcast (@TargetsPodcast) September 23, 2015
— Laura Strong (@scientre) September 22, 2015
— GRACE (@cancerGRACE) June 16, 2015
— AnneMarie Ciccarella (@chemobrainfog) April 30, 2015